A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-09-10
Target enrollment:
Participant gender:
Summary
A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of
6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.